Background. LL-37 is a host defense peptide with antimicrobial and immunomodulatory properties. We examined the relation of serum LL-37 levels to the severity of bronchiolitis and viral etiology.
demonstrated that lower levels of serum LL-37 in patients undergoing hemodialysis are associated with increased mortality rates [7] . In human and laboratory studies, LL-37 has been shown to have antiviral activity against RSV [8] [9] [10] , and reduce RV replication [11] .
Mansbach et al [12] previously reported in a pilot study of 82 children with bronchiolitis that serum human cathelicidin antimicrobial peptide levels less than the median were associated with more severe bronchiolitis (defined by hospitalization for ≥24 hours) and increased frequency of RSV infection (compared with RV). More recently, Hasegawa et al [13] reported that infants with lower levels of serum LL-37 and a Haemophilus-dominant airway microbiota are more likely to require intensive care; that analysis specifically examined the interaction between LL-37 and Haemophilus dominance but not the direct association between LL-37 and either severity of illness or viral etiology. This knowledge gap and the promise of LL-37 as an inducible host defense peptide with beneficial clinical effects [14] led us to reexamine our previous findings in a much larger sample of infants hospitalized with bronchiolitis.
METHODS

Study Design
We performed a prospective cohort study of hospitalized infants (aged <1 year) with an attending physician's diagnosis of bronchiolitis at 17 hospitals across the United States. Site teams enrolled hospitalized infants from 1 November to 30 April for 3 consecutive years (2011) (2012) (2013) (2014) . This study is called the 35th Multicenter Airway Research Collaboration, or MARC-35. MARC is a program of the Emergency Medicine Network (EMNet) (www. emnet-usa.org). One of the short-term goals of MARC-35 is to better understand the factors associated with severity of illness at the time of hospitalization. Its long-term goals are to determine factors associated with recurrent wheezing of childhood by age 3 years and eventual asthma at age 6 years.
We included families with children aged <1 year, and with a gestational age ≥32 weeks, who were hospitalized with an attending physician diagnosis of bronchiolitis, as defined by the Academy of Pediatrics; participating families agreed to longterm follow-up with a stable address, phone number, e-mail, and primary care provider and provided informed consent.
We excluded families who (1) did not agree to the collection of nasopharyngeal aspirate or blood; (2) agreed to participate >24 hours after admission to the ward or intensive care unit; (3) already met the definition of the primary outcome, recurrent wheezing (ie, 2 oral steroid courses in 6 months or 4 episodes of wheezing in past year); or (4) had known chronic medical conditions, such as heart-lung disease, immunodeficiency, or immunosuppression. All patients were treated at the discretion of the treating clinician. The institutional review board at each of the 17 participating hospitals approved the study.
Data Collection
Investigators conducted structured interviews to collect demographic characteristics, as well as detailed medical, environmental, nutritional, and family histories. Site teams also reviewed emergency department and hospital charts to collect details of the hospitalization.
Blood and Nasopharyngeal Aspirate Collection
All site teams collected blood samples as soon as possible during the hospitalization. All nasopharyngeal aspirates were collected within 24 hours of hospitalization using the same protocol and equipment (eg, sample traps and suction catheters from Medline Industries) used in previous studies [3, 15] .
LL-37 and 25-Hydroxyvitamin D Assays
We quantified serum LL-37 concentrations using the Hycult Biotech Human LL-37 enzyme-linked immunosorbent assay. We quantified 25- [16, 17] . Vitamin D-binding protein values were calculated using the Quantikine Human Vitamin D Binding Protein Immunoassay.
Polymerase Chain Reaction Assays
Polymerase chain reaction assays for 16 viruses were conducted at Baylor College of Medicine, as described elsewhere [18] [19] [20] . We tested all samples for RSV types A and B, RV, parainfluenza virus types 1, 2 and 3, influenza virus types A and B, human metapneumovirus, coronaviruses NL-63, HKU1, OC43 and 229E, adenovirus, human bocavirus type 1, and enterovirus.
16S Ribosomal RNA Gene Sequencing and Compositional Analysis
To examine the structure of microbiota, we also sequenced the 16S ribosomal RNA gene V4 region of the nasopharyngeal aspirates on the Illumina MiSeq platform. Only microbiota data with sufficient sequence depth (ie, rarefaction cutoff of 2128 readings per sample) were used. As described elsewhere [21] , we generated 4 distinct microbiota clusters using an unbiased clustering approach (ie, partitioning around medoids), weighted UniFrac distances [22] , and the average silhouette score [23] . The 4 airway microbiota clusters in the nasopharyngeal aspirate were: Haemophilus dominant, Moraxella dominant, Streptococcus dominant, and mixed.
Primary Exposure and Outcome Measures
For the present analysis, we categorized the serum LL-37 levels into quartiles: lowest (<34 ng/mL), second lowest (34-45.9 ng/mL), second highest (46-59.9 ng/mL), and highest (≥60 ng/mL). The primary outcome was severity of illness, defined as intensive care use (ie, admission to an intensive care unit or use of continuous positive airway pressure and/or intubation) at any time during the index hospitalization [15, 24] . The secondary measure of severity was hospital length of stay (LOS) as a count variable. The virus outcomes were RSV and RV, which included virus-only infections (ie, RSV only and RV only) and any combination of viral coinfection with RSV and RV, including the specific RSV-RV coinfection.
Statistical Methods
Across the LL-37 quartiles, we compared patient characteristics and hospital course using χ 2 [27, 28] -because these were considered intermediate or upstream factors, rather than confounders, for the associations of interest. Infant weight was not included because it is strongly correlated with age. We also fit locally weighted scatterplot smoothing (LOESS) plots that show the nonlinear relationship between LL-37 as a continuous variable and the 2 severity outcomes. Analyses used R version 3.3.1 with the lme4 package for the mixed-effects models and the phyloseq package [29] . All P values were 2 tailed, with differences considered statistically significant at P < .05.
RESULTS
Of the 1016 children enrolled in MARC-35, 1005 had complete data and comprised the analytic cohort. The median age at hospitalization was 3 months (interquartile range [IQR], 2-6 months), 60% were male, and 43% were non-Hispanic white. Overall, 161 (16%) infants hospitalized for bronchiolitis required intensive care use. The overall median hospital LOS was 2 days (IQR, 1-3). The infants included 813 (81%) infants with RSV infection, 211 (21%) with RV infection, and 120 (12%) with specific RSV-RV coinfection. Together, RSV and RV accounted for 90% of the bronchiolitis hospitalizations.
Overall, the median level of serum LL-37 was 46 ng/mL (IQR, 34-60 ng/mL). Table 1 shows patient characteristics, clinical variables, virology, airway microbiota clusters, and laboratory data by LL-37 quartile. In general, older infants who had attended daycare had significantly higher levels of LL-37. There were no differences in either serum 25(OH)D or bioavailable 25(OH)D by quartile of LL-37 in this acutely ill population.
LL-37 and Severity of Illness
The rate of intensive care use was highest in the infants with the lowest levels of LL-37 versus those with the highest levels (25% vs 13%; unadjusted odds ratio [OR], 2.29; P < .001; Tables  1 and 2 ). When LL-37 was examined as a continuous variable the inverse relationship between the level of LL-37 and intensive care use remained ( Figure 1 ). Furthermore, after adjustment for 12 factors (see Supplementary Figure S1 for LOESS plot of age and likelihood of intensive care) and clustering by site, the rate of intensive care use was significantly higher in children in the lowest quartile of LL-37, compared with those in the highest quartile (OR, 1.97; P = .01; Table 2 ). One of the unique factors in the present analysis was our ability to adjust for previously identified airway microbiota clusters [21] . As in previous reports, we found that a Haemophilus-dominant microbiota was significantly associated with intensive care [13, 21] .
The inverse relationship between serum LL-37 and severity of illness is further supported when hospital LOS is used as the outcome. The hospital LOS was longer in children in the lowest quartile of LL-37 levels, compared with those in the highest quartile (unadjusted rate ratio, 1.52; P < .001; Tables 1 and 3 ). This inverse relationship is again shown in the LOESS plot ( Figure 2 ). The significant association persisted in the multivariable results. After adjustment for the same 12 factors used in the intensive care model, infants in the lowest and second-lowest quartiles of LL-37 levels had significantly longer LOS than those in the highest quartile ( Table 3 ). The second-highest quartile of LL-37 levels had a nonsignificant association with longer LOS (Table 3) .
LL-37 and Viral Etiology
When we examined the proportions of children with RSV only and RV only by LL-37 quartile (Table 1) , there seemed to be a threshold effect. At the highest quartile of serum LL-37 levels, RSV-only infections are less common and RV-only infections are more common, compared with any of the other 3 quartiles (P < .001). This same pattern is seen in both the unadjusted and adjusted models. Compared with the highest quartile of LL-37 levels, infants with LL-37 levels in the 3 lowest quartiles were significantly more likely (OR, ≥2.14; P < .001) to have RSV bronchiolitis (Table 4) .The results are consistent even after adjustment for 11 factors and clustering by site (Table 4) . One factor we adjusted for was airway microbiota composition, and we found that a Streptococcus-dominant airway microbiota was positively associated with RSV. By contrast, RV infection is more common at the highest levels of LL-37. Compared with the highest quartile of LL-37 levels, infants in the 3 lowest quartiles were significantly less likely (OR, ≤0.62; P = .02) to have RV bronchiolitis (Table 5 ). The results are consistent even after adjustment for 11 factors and clustering by site (Table 5) .
DISCUSSION
In this multicenter cohort study of >1000 infants hospitalized with bronchiolitis we found that lower levels of serum LL-37 (ie, cathelicidin) during hospitalization were significantly associated with increased intensive care and longer hospital LOS, even after adjusting for multiple patient level factors. We also found that infants in the highest quartile of serum LL-37 were less likely to have RSV bronchiolitis but more likely to have RV bronchiolitis. These results corroborate and extend previous findings from a small multicenter study (n = 82) that first linked low levels of serum cathelicidin to more severe bronchiolitis and RSV [12] . (36) 93 (36) 85 (32) .68 Prematurity (32-37 wk) 48 (21) 44 (19) 48 (18) 43 (16) .55 Breathing problems before index hospitalization c 40 (17) 40 (17) 54 (20) 69 (25) .07 History of eczema 39 (17) 26 (11) 35 (13) (14) 38 (14) 34 (13) . LL-37 is a part of the innate immune response and has extensive antimicrobial and immunomodulatory effects [10, 30] that have been shown to influence the severity of pulmonary conditions and mortality in murine and human studies. In mice, cathelicidin-related antimicrobial peptide, improved lung bacterial clearance and survival in response to Klebsiella pneumoniae [31] . In humans, cross-sectional analyses found that higher LL-37 levels (median, 36 ng/mL; IQR, 28.8-45.9) were associated with improved forced expiratory volume in one second of expiration [32] . Moreover, in 112 adults hospitalized with community-acquired pneumonia, values of serum LL-37 in the lowest tertile (overall median, 69 ng/mL; range, 13-263 ng/mL) were associated with a higher 30-day mortality (P = .053) [33] . In a nested case-control study among individuals initiating chronic hemodialysis (n = 279), patients with serum cathelicidin levels in the lowest tertile had an increased rate of death due to infection over 1 year (adjusted OR, 3.7; 95% confidence interval, 1.2-11.2) [7] .
Concordant with these results and previous findings in 82 children with bronchiolitis [12] , the present data demonstrate an inverse association between serum levels of LL-37 and severity of illness. It is unclear from these data, however, whether the higher serum LL-37 levels preceded the infection, were in response to it, or were due to confounding by a third factor. Indeed, neither these data nor previous studies have established causality between the serum level of LL-37 and severity of illness. However, given the underlying biology of LL-37 and the preponderance of data, further study of LL-37 as a potential treatment for bronchiolitis requiring intensive care seems warranted.
The present data suggest that higher circulating levels of LL-37 may be particularly useful for children with RSV bronchiolitis. LL-37 has direct antiviral effects against RSV [8] [9] [10] , but it has also been shown to reduce RV replication in cystic fibrosis cells [11] . Our results, however, show a contrast between the relation of the LL-37 level and the viral etiology. Specifically, infants with serum LL-37 levels in the highest quartile were less likely to have RSV but more likely to have RV when compared with the other 3 LL-37 quartiles. We have now found in 2 separate bronchiolitis studies that high levels of LL-37 are associated with a decreased likelihood of RSV [12] . The new finding that high LL-37 levels were associated with RV is intriguing. Children with RV bronchiolitis have been shown in 2 separate cohorts to have shorter LOS (ie, lower severity of illness) than children with RSV bronchiolitis [3, 34] . The present data show that higher LL-37 levels are associated with less severe bronchiolitis. Although interesting, the details of the observed relationship between higher LL-37 levels, RV bronchiolitis, and decreased severity of illness are beyond the scope of the current results.
Bronchiolitis, however, is not simply a viral illness. The viruses that infect infants do so in an airway colonized with bacteria [21, 35] . Indeed, we found that children hospitalized with RSV or RV bronchiolitis have reproducible and distinct airway microbiota [35] , including the RSV-Streptococcus association seen in the present data. We have also found that the severity of bronchiolitis is related not only to clinical factors [36] but also to the composition of the airway microbiota [21] . Specifically, when compared with a Moraxella-dominant airway microbiota, infants with a Haemophilus-dominant airway microbiota have more severe bronchiolitis [21] , especially infants with low serum LL-37 levels [13] . Taken together, the present LL-37 results and previous data about viral-bacterial interactions suggest a complex interplay between the virus, the airway microbiota, and the host response. Ongoing multi-omic research and systems biology approaches will be needed to address these complex relationships.
Despite the complexity of the pathobiology of bronchiolitis, the association between vitamin D and cathelicidin provides one potential direction for treatment. In vitro 1,25-dihydroxyvitamin D increases the transcription of cathelicidin [37] and in vivo, vitamin D administration induces cathelicidin [27, 28] . In the present data and similar to previously reported findings [12] , [27] . Given the lack of beneficial pharmacotherapies for infants with bronchiolitis [38] , these data support ongoing studies examining the induction of LL-37 using vitamin D [27] . In a separate, but related line of inquiry, these data also support efforts to create a synthetic, administrable version of cathelicidin [39] .
The current study has several potential limitations. First, the study population was hospitalized infants, and the results may not be generalizable to infants in the outpatient setting. However, the results are relevant for the approximately 130 000 infants who are hospitalized with bronchiolitis every year [2] . Second, the LL-37 levels were measured during the hospitalization, and prospective data are needed to understand the dynamics of LL-37 before the Mixed-effects logistic regression models adjusting for sites as random effects. c Significant at P < .05. symptoms of bronchiolitis develop or early in the course of the illness. However, because only 3% of children with bronchiolitis require hospitalization [2] , obtaining blood from infants before hospitalization would be technically and ethically challenging. Nonetheless, the present results suggest that further study of LL-37 in bronchiolitis is warranted. Third, it was beyond the scope of the present study to determine the specific cellular source (ie, neutrophils, epithelial cells, or macrophages) of the circulating LL-37. Finally, the timing of the increase in LL-37 and the LL-37 level required to potentially improve outcomes for infants with bronchiolitis remains uncertain. Finally, this observational study cannot prove causality between LL-37 levels and severity of illness or viral etiology. Nonetheless, the observed associations in the present data recapitulate previous findings [12] and remained significant after adjustment for multiple confounders and sites of care.
In this large, multicenter, ethnically diverse cohort of infants hospitalized with bronchiolitis, we found an inverse association between the level of LL-37 during hospitalization and the severity of illness, as measured by intensive care use and LOS. We also found an inverse relationship with RSV. Specifically, lower levels of LL-37 were associated with increased severity and RSV bronchiolitis. By contrast, higher levels of LL-37 were positively associated with RV. These findings support further investigation examining the role of LL-37 in bronchiolitis pathogenesis.
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